Humbert took to LinkedIn to announce the move:
“I am excited to share that I have recently taken on the role of CEO at Brightflow,” she wrote. “This innovative company is focused on designing an implantable cardiac pump that has the potential to revolutionize the healthcare industry. I am thrilled to be a part of such a groundbreaking organization and look forward to leading the team to new heights.”
Humbert spent nearly seven years at Limflow, a France-based chronic limb-threatening ischemia (CLTI) treatment maker. LimFlow designed its system for transcatheter arterialization of deep veins. It diverts blood from a diseased tibial artery to a tibial vein to deliver oxygen to a patient’s ischemic foot.
LimFlow won FDA premarket approval (PMA) for its breakthrough CLTI treatment in September 2023. Not long after, Inari Medical closed a $415 million acquisition of the company in November 2023.
Karista, a venture capital firm, lists Humbert’s new company, Brightflow, as an active investment in its portfolio. Karista invested in Brightflow in 2021. The firm’s website says France-based Brightflow “develops a first-of-a-kind implantable medical device to treat heart failures.” As Humbert said in her LinkedIn post, the device is an implantable heart pump of some kind.
